Analysis Glenmark Pharmaceuticals Limited (GLENMARK)
5/31/2024
Analysis of Glenmark Pharmaceuticals Limited (GLENMARK)
Glenmark Pharmaceuticals Limited has shown a consistent upward trend in its stock price over the past few days. The Relative Strength Index (RSI) values have been consistently above 50, indicating a strong bullish momentum. The Moving Average Convergence Divergence (MACD) indicator also shows positive values, suggesting a bullish trend.On May 31st, the stock closed at 1160.75, with RSI at 70.16 and MACD at 34.39, indicating a strong bullish sentiment. The stock has been trading above its Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA), further supporting the bullish trend.
Overall, based on the RSI, MACD, and moving averages, Glenmark Pharmaceuticals Limited seems to be in a strong bullish phase, and investors may consider this stock for further analysis and potential investment opportunities.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous results were reported on February 27, 2025, by the Transfer Agent. Before that, on January 31, 2025, the results were released after hours. The results from October 31, 2024, were not provided at the time. On August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio and a high total debt to equity ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and the most recent quarter reported is March 2024. The company shows good returns on assets and equity.
Looking at stock statistics, the company has a low short ratio and a significant percentage held by institutions. The stock has a beta of 1.264 and has been trading within a range between its fifty-two-week low and high.
Valuation metrics show a relatively high PEG ratio and forward PE ratio. The company's market capitalization and enterprise value are substantial, with a high price to book and price to sales ratios. The enterprise value to EBITDA and revenue ratios are also notable.
The stock price summary includes moving averages, fifty-two-week range, and beta, providing insights into the stock's performance and volatility.
Lastly, dividends and splits information show the company's dividend history, payout ratio, and upcoming dividend dates. The company has a history of dividend payments and a moderate dividend yield.
Income statement 💸
These are the revenues. Here are the conclusions:1. The company's sales have been increasing steadily over the past four fiscal years.
2. The EBITDA has also shown a positive trend, indicating strong operational performance.
3. Net income has been growing consistently, reflecting the company's profitability.
4. Earnings per share (EPS) have shown slight fluctuations but have generally been stable.
5. The company has been able to maintain a healthy gross profit margin despite fluctuations in the cost of goods sold.
6. Operating income has been increasing, showing efficient management of operating expenses.
7. The company has been able to generate income from non-operating interests, contributing to its overall profitability.
8. The number of basic and diluted shares outstanding has remained relatively stable over the years.
9. Overall, the financial performance of the company, as indicated by its revenues, has been positive and shows a growth trajectory.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have shown an increasing trend, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Current liabilities have fluctuated, with the highest value in 2019 at $105,718,000,000.
6. Non-current liabilities have shown an increasing trend, with the highest value in 2019 at $142,310,000,000.
7. Shareholders' equity has shown an increasing trend, reaching $107,147,000,000 in 2018.
8. Retained earnings have been positive in all years except for 2022, where it was negative at -$3,068,000.
9. The company has been investing more in non-current assets and has been relying more on long-term debt to finance its operations.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with a focus on operational efficiency and strategic investments.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.33, with a low estimate of $1.27 and a high estimate of $1.36. This shows growth compared to the EPS of $1.26 from a year ago.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.53, with a low estimate of $1.44 and a high estimate of $1.63. This indicates an increase from the EPS of $1.46 from a year ago.
3. For the current fiscal year ending on September 30, 2024, the average EPS estimate is $6.59, with a low estimate of $6.43 and a high estimate of $6.92. This reflects growth compared to the EPS of $6.13 from the previous year.
4. Looking ahead to the next fiscal year ending on September 30, 2025, the average EPS estimate is $7.23, with a low estimate of $6.40 and a high estimate of $7.90. This suggests an improvement from the EPS of $6.59 reported for the previous year.
Overall, the analysts' estimates point towards a positive outlook for the company's earnings per share in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided:- The current year growth rate is 7.5%
- The next quarter growth rate is 4.8%
- The current quarter growth rate is 5.6%
- The next year growth rate is 9.7%
- The next 5 years compound annual growth rate (CAGR) is 11%
- The past 5 years compound annual growth rate (CAGR) is 20.15%
It can be observed that the company is expected to experience a significant increase in growth compared to the past 5 years, with a particularly high growth rate projected for the next 5 years. This indicates positive expectations and potential for expansion in the company's performance.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the low end at $164, the high end at $250, and the average forecast at $202.26. The current price is below both the average and median forecast, indicating that there is potential upside according to the analysts' predictions.
MACD of GLENMARK
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
